Medical Device India Head Search — MNC Subsidiary, Domestic Manufacturer and PLI-Scheme Contexts

An MNC medical device India CEO runs the India subsidiary P&L of a global device parent — most commonly in cardiovascular, orthopaedics, diagnostics, IVD, or surgical segments. The role has matured over 2020–26 from a commercial-led distribution business to a development-and-manufacturing-led business for several MNC parents, driven by the PLI-scheme incentive for local manufacturing and the India-as-a-strategic-market narrative at global Boards. Typical scope spans CDSCO interaction, hospital-KOL engagement, distributor network management, direct-commercial salesforce (where present), tender and GeM-portal management, and medical-affairs leadership. Compensation is capped by parent-company global framework with global-RSU LTI.

A domestic medical device manufacturer CEO runs a manufacturing-led business with direct CDSCO registration, export market exposure (USFDA 510(k), CE mark, ANVISA), and often PLI-scheme capex programmes driving capacity expansion. The KPI stack is capacity utilisation, export-market revenue growth, domestic commercial scale-up, and capex-programme completion on PLI timelines. The candidate pool overlaps with returning-diaspora candidates from US / EU medical-device companies, MNC Country GMs with prior manufacturing exposure, and specialty-chemical or process-industry CEOs with medical-device-adjacent transitions.

• •Manufacturing architecture — capacity planning, clean-room design, process validation, quality management system (ISO 13485, 21 CFR 820 equivalents).
• •Regulatory posture — CDSCO primary; USFDA 510(k), CE-mark and ANVISA for export-facing businesses.
• •Export-market architecture — USA, EU, LATAM and MENA market penetration, distribution partner selection.
• •PLI capex programme — scope, timeline, incentive-claim mechanics, and post-PLI operating architecture.
• •Commercial architecture — hospital-KOL engagement, distributor network, tender and public-procurement fluency.

• •CDSCO regulatory posture — named registration, import-licence, and notified-body experience across the Medical Devices Rules 2017 framework.
• •Manufacturing / quality architecture — ISO 13485 and 21 CFR 820 (or equivalent) depth if manufacturing-led; USFDA 510(k) or CE-mark for exports.
• •Commercial architecture — hospital KOL engagement, distributor management, tender and GeM-portal fluency.
• •Capex and PLI-programme discipline — named multi-hundred-crore capex programmes owned with PLI-incentive claim mechanics.
• •Segment depth — cardiovascular, orthopaedics, diagnostics, IVD, surgical, digital health — specific to the mandate.
• •Medical-affairs and clinical-evidence architecture — post-market surveillance, clinical-investigation design, hospital-data partnerships.
• •Leadership bench — India Quality Head, Commercial Head, Medical Affairs Head, and Regulatory Head the candidate has built and retained.

1. 1.Mandate brief with the Global sponsor (MNC) or Chair / PE sponsor (domestic) — identifying context and segment.
2. 2.Persona engineering — competency matrix weighted by context (MNC vs domestic manufacturer vs segment specialist) and PLI-exposure.
3. 3.Sector mapping — Gladwin's live medical device leader map of ~110 candidates segmented by segment and context.
4. 4.Longlist research — 20–30 candidates with three-page profiles covering segment P&L, regulatory track record, and manufacturing / capex credentials.
5. 5.Discreet partner-led approach — phone-first contact, sanitised mandate brief, NDAs before detail shared.
6. 6.Pre-qualification — 90-minute partner interviews on regulatory philosophy, segment architecture, and first-180-days mandate plan.
7. 7.Competency assessment — structured scoring plus a written CDSCO-navigation or PLI-capex vignette on a sanitised context.
8. 8.Reference triangulation — minimum six references including Chair / Global sponsor, peer CXO, medical director or KOL partner from prior role, and at least one distributor / export-partner reference.
9. 9.Shortlist — three candidates to the Chair / Global sponsor with comparative scoring and a detailed regulatory-posture memo.
10. 10.Offer structuring under MNC global framework (where applicable) or PE-backed ESOP structure (where applicable), and a 100-day integration plan covering regulatory-team engagement, capex-programme review, and hospital-KOL engagement plan.